Paul Sanger interviewed Damian Spring, CEO of Santana Minerals Limited (ASX:SMI), to discuss the Bendigo gold project, which has recently been designated as a fast-track project. Damian highlighted the project's economic potential, projecting 1.1 million ounces of gold over ten years, which could generate significant export earnings and job creation in New Zealand. He mentioned ongoing environmental studies and a feasibility study set for release soon, emphasising the positive impact of rising gold prices on profitability and investor interest.
Copyright 2024 – Finance News Network
24 Feb 2021 - Shaw and Partners Chief Investment Officer Martin Crabb provides an update on the global economy, US stimulus packages, rising bond yields and their implications for investors.
20 Dec 2023 - Explore the latest developments with BluGlass CEO Jim Haden as he delves into the company's significant defense contract win and the strategic acquisition of GaNWorks. Discover how these milestones drive BluGlass' position at the forefront of quantum laser innovation in 2024, unlocking new potentials in defense, quantum computing, and beyond.
07 Sep 2022 - IVE Group (ASX:IGL) Executive Chairman Geoff Selig discusses full-year results, the recent acquisition of Ovato and the launch of the Lasoo e-commerce platform.
22 Aug 2022 - archTIS Limited (ASX:AR9) CEO and Managing Director Daniel Lai discusses AR9's client base and growth plans, international markets, and collaborations with Microsoft and KPMG.
01 Mar 2024 - Shaw and Partners Chief Investment Office Martin Crabb discusses the leading indicators for equity markets, financial conditions and central banks.
04 Mar 2024 - Andrew Radonjic - Managing Director - Venture Minerals (ASX:VMS) is dedicated to discovering and developing world-class mineral deposits to meet global demand for critical minerals vital to the green energy transition.
24 Jun 2020 - Immutep (ASX:IMM) CEO, Marc Voigt provides an update on its clinical trials including metastatic breast cancer (MBC), its global leadership under Chief Scientist and Medical Officer, Professor Frederic Triebel, and the growing interest by big pharma in immuno-therapies.
